RecruitingNot ApplicableNCT06168292

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma: A Prospective, Single-arm, Multicenter Study


Sponsor

National Cancer Center, Korea

Enrollment

53 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

\[Study objectives\] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.


Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination treatment for bile duct cancer (specifically the ducts outside the liver) that cannot be removed by surgery. The treatment uses heat-based ablation delivered through a scope, combined with radiation therapy, to try to shrink or control the cancer. **You may be eligible if...** - You are 20 years or older - You have been diagnosed with inoperable bile duct cancer outside the liver, confirmed by a lab test - You are willing to participate and can sign a consent form **You may NOT be eligible if...** - You refuse to sign informed consent - Your cancer has spread to other parts of the body (stage IV) or you have fluid buildup in the abdomen - Your cancer is inside the liver (intrahepatic) - You cannot safely undergo an endoscopic (scope) procedure - Your life expectancy is 3 months or less - You have a pacemaker, are pregnant, or have uncontrolled bleeding problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREID-RFA and Radiotherapy

The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.


Locations(1)

National Cancer Center, Korea

Goyang-si, Other, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06168292


Related Trials